Pfizer Overseas Pharmaceuticals v Eli Lilly and Company

Pfizer Overseas Pharmaceuticals, the respondent, appealed against a decision of the Federal Court of Australia that found claim 10 of their patent for a pharmaceutical composition to be invalid. Eli Lilly and Company, the appellant, sought to invalidate the patent on various grounds including lack of inventive step, insufficiency, and failure to fairly base the claims on the specification. The case involved a detailed understanding of the physiological and biochemical processes of erectile function in the human penis and the potential therapeutic use of PDE VA inhibitors.

The primary legal issue before the court was whether claim 10 of Pfizer's patent was valid. The court had to determine if the patent specification sufficiently disclosed the invention, if the invention was obvious, and if claim 10 was fairly based on the specification. The court also had to consider whether the patent disclosed a false suggestion and if it complied with the best method requirement.

The court found that Pfizer had successfully demonstrated error in the primary judge's finding regarding the lack of inventive step. However, it upheld the primary judge's finding that claim 10 was not fairly based on the specification. The court concluded that claim 10 was invalid due to the lack of fair basis and dismissed the appeal. The court ruled that each party should bear its own costs of the appeal due to the distribution of success and failure.

The court's decision was that the appeal be dismissed and that the parties bear their own costs of the appeal. This outcome ensures that Pfizer's patent claim 10 remains invalid due to the lack of fair basis in the specification.